AVADEL PHARMACEUTICALS PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.81 USD | +1.76% |
|
-9.72% | +17.00% |
Presenter SpeechGregory Divis (Executives)First of all, thank you for everyone here in person ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Avadel Pharmaceuticals PLC is a biopharmaceutical company. The Company's lead product, LUMRYZ, is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. Its approach includes applying solutions to the development of medications that address the patients face with treatment options. Its drug delivery technologies include MICROPUMP, LIQUITIME and MEDUSA. Its MICROPUMP technology allows for the development of modified release solid, oral dosage formulations of drugs. Its LIQUITIME technology allows for the development of modified release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its MEDUSA technology allows for the development of modified-release injectable dosage formulations of drugs.
Sector
Pharmaceuticals
Calendar
2024-08-06
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
16.52
USD
Average target price
23.65
USD
Spread / Average Target
+43.16%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +17.00% | 1.5B | |
| +29.98% | 684B | |
| +30.34% | 568B | |
| -3.52% | 361B | |
| +18.59% | 329B | |
| +4.07% | 284B | |
| +16.21% | 240B | |
| +9.66% | 208B | |
| -6.83% | 200B | |
| +7.09% | 166B |
- Stock Market
- Equities
- AVDL Stock
- News Avadel Pharmaceuticals plc
- Transcript : Avadel Pharmaceuticals plc - Special Call